Remix Therapeutics, a Cambridge, MA-based clinical-stage biotechnology company developing small molecule therapies, raised $60M in funding.

The round was led by The Column Group with participation from existing investors Atlas Venture, Foresite Capital, Alexandria Venture Investments, Arch Venture Partners, Casdin Capital, and Surveyor along with new investors WTT Investment, Willett Advisors, and others.

The company intends to use the funds to support clinical development of its lead program, REM-422, and further advancement of a pipeline of RNA processing targeted therapeutics.

Led by CEO and Ph.D. Peter Smith, Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. RNA processing is the pathway that controls gene and protein expression. The REMaster technology platform facilitates RNA processing pattern identification, leveraging these learnings to identify and target key RNA processing steps to modulate gene expression. Its therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin.

Huge congratulations to Remix Therapeutics for closing a remarkable $60M in financing! What an incredible milestone. Wishing the Remix Therapeutics team continued success as they pave the way for innovation and impact in the field. πŸš€πŸ’°

~ Dr Shishir said Gupta founder & CEO of StartupLanes 

About us: StartupLanes is an ecosystem for Startups and Investors. Collaborate or find a co-founder, it’s a platform for Entrepreneurs. We love startups! A place for Angel Investors and Venture Capitalists to find investing opportunities in startups. Validate your idea, Learn & Execute.

Startups looking for funding may apply through StartupLanes Funding Application.

Angel Investors Register Free to explore exciting startup investment opportunities.